What is Lifesci Capital's Forecast for OLMA FY2025 Earnings?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Investment analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Olema Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky forecasts that the company will post earnings of ($2.12) per share for the year. The consensus estimate for Olema Pharmaceuticals' current full-year earnings is ($2.32) per share.

Several other equities analysts have also weighed in on OLMA. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. dropped their price objective on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Finally, Oppenheimer reissued an "outperform" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, August 7th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $27.00.

Olema Pharmaceuticals Trading Down 9.2 %

Shares of NASDAQ:OLMA traded down $0.93 during midday trading on Friday, reaching $9.17. The company had a trading volume of 591,589 shares, compared to its average volume of 736,101. The stock has a market cap of $525.42 million, a P/E ratio of -4.43 and a beta of 2.02. The company's 50 day moving average price is $12.05 and its 200 day moving average price is $11.96. Olema Pharmaceuticals has a 52-week low of $8.51 and a 52-week high of $17.10.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.01).

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new position in Olema Pharmaceuticals in the second quarter valued at $34,753,000. Great Point Partners LLC purchased a new stake in Olema Pharmaceuticals in the second quarter worth approximately $8,622,000. Candriam S.C.A. raised its stake in shares of Olema Pharmaceuticals by 199.9% during the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company's stock worth $11,454,000 after acquiring an additional 705,655 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Olema Pharmaceuticals by 74.5% in the 1st quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company's stock worth $13,817,000 after acquiring an additional 521,562 shares during the last quarter. Finally, Affinity Asset Advisors LLC bought a new position in shares of Olema Pharmaceuticals during the 2nd quarter valued at $2,976,000. Hedge funds and other institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.